Evaluation of the safety and efficacy of daratumumab outside of clinical trials. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-08

AUTHORS

Hiroki Kobayashi, Takafumi Tsushima, Toshiki Terao, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue

ABSTRACT

Daratumumab-based therapy has been shown to have significant clinical efficacy in phase 3 trials of patients with relapse or refractory multiple myeloma. Outside of clinical trials, however, clinical data on daratumumab remain limited. We reviewed medical records of patients who received daratumumab combination therapy at our institute (median age 74 years; median lines of prior therapy 4). The overall response rate was 69.4%, and 36.7% of patients achieved complete response (CR) or better. The proportion of patients who attained CR or better was significantly higher among patients with < 4 prior therapies than those with ≥ 4 (56.5% vs 19.2%, P = 0.009). Estimated median progression-free survival (PFS) was 12.4 months (95% confidence interval 8.6-not reached). The median PFS was significantly worse in patients who were refractory to bortezomib and lenalidomide and had received ≥ 4 lines of prior therapy. Twelve of 49 patients attained negative minimal residual disease. Common adverse events included hematological toxicities including neutropenia and lymphopenia; however, the rate of febrile neutropenia was low (3.8%). Infusion-related reactions occurred in 32.1% of patients, but were grade 1 or 2. Daratumumab combination therapies therefore appear to be effective and safe as salvage regimens in clinical practice, especially when used in the early phase. More... »

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-019-02648-4

DOI

http://dx.doi.org/10.1007/s12185-019-02648-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113301205

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30963473


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan. hiro.k2302@gmail.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobayashi", 
        "givenName": "Hiroki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsushima", 
        "givenName": "Takafumi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Terao", 
        "givenName": "Toshiki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abe", 
        "givenName": "Yoshiaki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miura", 
        "givenName": "Daisuke", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narita", 
        "givenName": "Kentaro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kitadate", 
        "givenName": "Akihiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takeuchi", 
        "givenName": "Masami", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kameda Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414927.d", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsue", 
        "givenName": "Kosei", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3324/haematol.2010.030759", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003844004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)01120-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009614699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)01120-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009614699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1606038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010220122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2015-10-646810", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017749361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70442-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021088092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70442-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021088092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026245496", 
          "https://doi.org/10.1038/leu.2013.313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026245496", 
          "https://doi.org/10.1038/leu.2013.313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1607751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026669052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2012.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028358194", 
          "https://doi.org/10.1038/bmt.2012.244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2015.356", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035584393", 
          "https://doi.org/10.1038/leu.2015.356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.550", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040390603"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2016-03-705210", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040939015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30206-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042996950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.1003032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051064690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/19420862.2015.1007813", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058413271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2017-05-785246", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086132764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.24883", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091157900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-017-2390-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099728472", 
          "https://doi.org/10.1007/s12185-017-2390-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41408-018-0071-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103640953", 
          "https://doi.org/10.1038/s41408-018-0071-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41408-018-0071-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103640953", 
          "https://doi.org/10.1038/s41408-018-0071-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41408-018-0071-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103640953", 
          "https://doi.org/10.1038/s41408-018-0071-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2018-05-850727", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107092876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2018.194282", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107121218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2018.194282", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107121218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2018.194118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107121220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2018.194118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107121220"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-08", 
    "datePublishedReg": "2019-04-08", 
    "description": "Daratumumab-based therapy has been shown to have significant clinical efficacy in phase 3 trials of patients with relapse or refractory multiple myeloma. Outside of clinical trials, however, clinical data on daratumumab remain limited. We reviewed medical records of patients who received daratumumab combination therapy at our institute (median age 74\u00a0years; median lines of prior therapy 4). The overall response rate was 69.4%, and 36.7% of patients achieved complete response (CR) or better. The proportion of patients who attained CR or better was significantly higher among patients with\u2009<\u20094 prior therapies than those with\u2009\u2265\u20094 (56.5% vs 19.2%, P\u2009=\u20090.009). Estimated median progression-free survival (PFS) was 12.4\u00a0months (95% confidence interval 8.6-not reached). The median PFS was significantly worse in patients who were refractory to bortezomib and lenalidomide and had received\u2009\u2265\u20094 lines of prior therapy. Twelve of 49 patients attained negative minimal residual disease. Common adverse events included hematological toxicities including neutropenia and lymphopenia; however, the rate of febrile neutropenia was low (3.8%). Infusion-related reactions occurred in 32.1% of patients, but were grade 1 or 2. Daratumumab combination therapies therefore appear to be effective and safe as salvage regimens in clinical practice, especially when used in the early phase.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12185-019-02648-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "type": "Periodical"
      }
    ], 
    "name": "Evaluation of the safety and efficacy of daratumumab outside of clinical trials.", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-019-02648-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113301205"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9111627"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30963473"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-019-02648-4", 
      "https://app.dimensions.ai/details/publication/pub.1113301205"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T08:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000374_0000000374/records_119732_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s12185-019-02648-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02648-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02648-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02648-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02648-4'


 

This table displays all metadata directly associated to this object as RDF triples.

174 TRIPLES      20 PREDICATES      45 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-019-02648-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N0a38649cbd1f4606a2a061b664cca9bd
4 schema:citation sg:pub.10.1007/s12185-017-2390-2
5 sg:pub.10.1038/bmt.2012.244
6 sg:pub.10.1038/leu.2013.313
7 sg:pub.10.1038/leu.2015.356
8 sg:pub.10.1038/s41408-018-0071-x
9 https://doi.org/10.1002/ajh.24883
10 https://doi.org/10.1002/cpt.550
11 https://doi.org/10.1016/s0140-6736(15)01120-4
12 https://doi.org/10.1016/s1470-2045(14)70442-5
13 https://doi.org/10.1016/s1470-2045(16)30206-6
14 https://doi.org/10.1056/nejmoa1606038
15 https://doi.org/10.1056/nejmoa1607751
16 https://doi.org/10.1080/19420862.2015.1007813
17 https://doi.org/10.1182/blood-2015-10-646810
18 https://doi.org/10.1182/blood-2016-03-705210
19 https://doi.org/10.1182/blood-2017-05-785246
20 https://doi.org/10.1182/blood-2018-05-850727
21 https://doi.org/10.3324/haematol.2010.030759
22 https://doi.org/10.3324/haematol.2018.194118
23 https://doi.org/10.3324/haematol.2018.194282
24 https://doi.org/10.4049/jimmunol.1003032
25 schema:datePublished 2019-04-08
26 schema:datePublishedReg 2019-04-08
27 schema:description Daratumumab-based therapy has been shown to have significant clinical efficacy in phase 3 trials of patients with relapse or refractory multiple myeloma. Outside of clinical trials, however, clinical data on daratumumab remain limited. We reviewed medical records of patients who received daratumumab combination therapy at our institute (median age 74 years; median lines of prior therapy 4). The overall response rate was 69.4%, and 36.7% of patients achieved complete response (CR) or better. The proportion of patients who attained CR or better was significantly higher among patients with < 4 prior therapies than those with ≥ 4 (56.5% vs 19.2%, P = 0.009). Estimated median progression-free survival (PFS) was 12.4 months (95% confidence interval 8.6-not reached). The median PFS was significantly worse in patients who were refractory to bortezomib and lenalidomide and had received ≥ 4 lines of prior therapy. Twelve of 49 patients attained negative minimal residual disease. Common adverse events included hematological toxicities including neutropenia and lymphopenia; however, the rate of febrile neutropenia was low (3.8%). Infusion-related reactions occurred in 32.1% of patients, but were grade 1 or 2. Daratumumab combination therapies therefore appear to be effective and safe as salvage regimens in clinical practice, especially when used in the early phase.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf sg:journal.1076985
32 schema:name Evaluation of the safety and efficacy of daratumumab outside of clinical trials.
33 schema:productId N5bec097f5fb64da1941399df69233484
34 Nceba77f9f5aa4a1e986c678162279fce
35 Nd37b31f9274b4504bb328764fa11600c
36 Ne2b5dd7f870c42f0abdceccfd0122c6d
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113301205
38 https://doi.org/10.1007/s12185-019-02648-4
39 schema:sdDatePublished 2019-04-15T08:51
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher N1195fd7132e84225a940cfea3775b202
42 schema:url http://link.springer.com/10.1007/s12185-019-02648-4
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N0a38649cbd1f4606a2a061b664cca9bd rdf:first N1dc94462f0ce4217992441ab226c7d37
47 rdf:rest Ne869bea2c3bd405ca7fdd7d872325bd6
48 N1195fd7132e84225a940cfea3775b202 schema:name Springer Nature - SN SciGraph project
49 rdf:type schema:Organization
50 N11e689034e874fd9af0ca1259a185a8f rdf:first N9d3e49459fcb4a11946a106d975835cd
51 rdf:rest Nfa300708f917499ebd17b930bd306cf7
52 N1dc94462f0ce4217992441ab226c7d37 schema:affiliation https://www.grid.ac/institutes/grid.414927.d
53 schema:familyName Kobayashi
54 schema:givenName Hiroki
55 rdf:type schema:Person
56 N2136dd5232ec4ae6b09e06023c409ae4 schema:affiliation https://www.grid.ac/institutes/grid.414927.d
57 schema:familyName Miura
58 schema:givenName Daisuke
59 rdf:type schema:Person
60 N254de1bd2c2a4f5bb22d55da1b8600b3 schema:affiliation https://www.grid.ac/institutes/grid.414927.d
61 schema:familyName Kitadate
62 schema:givenName Akihiro
63 rdf:type schema:Person
64 N3f38aa0c7ce44fd4a8673dc96eb36d8d schema:affiliation https://www.grid.ac/institutes/grid.414927.d
65 schema:familyName Abe
66 schema:givenName Yoshiaki
67 rdf:type schema:Person
68 N3fa6e80f336c493bab4e22fc357a0635 rdf:first N3f38aa0c7ce44fd4a8673dc96eb36d8d
69 rdf:rest Nce9c56ded63b4cda825c8eec49301193
70 N495063f9e6e246bbb2e0193ce08eaf3b schema:affiliation https://www.grid.ac/institutes/grid.414927.d
71 schema:familyName Matsue
72 schema:givenName Kosei
73 rdf:type schema:Person
74 N55a40c3bb82344b6a70b36e9bebf087d schema:affiliation https://www.grid.ac/institutes/grid.414927.d
75 schema:familyName Tsushima
76 schema:givenName Takafumi
77 rdf:type schema:Person
78 N5bec097f5fb64da1941399df69233484 schema:name pubmed_id
79 schema:value 30963473
80 rdf:type schema:PropertyValue
81 N61051c45e00d4a71a7f2965cdf73cef8 rdf:first Nab72b48cf13a46f5927d12f5ceb8004e
82 rdf:rest N9bbeaab3f18a4ea3915cf4d1672fe828
83 N920d69043a824c6ca34475230e2136a3 rdf:first Ncf8c9093b8934a9487957c5e6c3fafb9
84 rdf:rest N3fa6e80f336c493bab4e22fc357a0635
85 N9bbeaab3f18a4ea3915cf4d1672fe828 rdf:first N495063f9e6e246bbb2e0193ce08eaf3b
86 rdf:rest rdf:nil
87 N9d3e49459fcb4a11946a106d975835cd schema:affiliation https://www.grid.ac/institutes/grid.414927.d
88 schema:familyName Narita
89 schema:givenName Kentaro
90 rdf:type schema:Person
91 Nab72b48cf13a46f5927d12f5ceb8004e schema:affiliation https://www.grid.ac/institutes/grid.414927.d
92 schema:familyName Takeuchi
93 schema:givenName Masami
94 rdf:type schema:Person
95 Nce9c56ded63b4cda825c8eec49301193 rdf:first N2136dd5232ec4ae6b09e06023c409ae4
96 rdf:rest N11e689034e874fd9af0ca1259a185a8f
97 Nceba77f9f5aa4a1e986c678162279fce schema:name dimensions_id
98 schema:value pub.1113301205
99 rdf:type schema:PropertyValue
100 Ncf8c9093b8934a9487957c5e6c3fafb9 schema:affiliation https://www.grid.ac/institutes/grid.414927.d
101 schema:familyName Terao
102 schema:givenName Toshiki
103 rdf:type schema:Person
104 Nd37b31f9274b4504bb328764fa11600c schema:name nlm_unique_id
105 schema:value 9111627
106 rdf:type schema:PropertyValue
107 Ne2b5dd7f870c42f0abdceccfd0122c6d schema:name doi
108 schema:value 10.1007/s12185-019-02648-4
109 rdf:type schema:PropertyValue
110 Ne869bea2c3bd405ca7fdd7d872325bd6 rdf:first N55a40c3bb82344b6a70b36e9bebf087d
111 rdf:rest N920d69043a824c6ca34475230e2136a3
112 Nfa300708f917499ebd17b930bd306cf7 rdf:first N254de1bd2c2a4f5bb22d55da1b8600b3
113 rdf:rest N61051c45e00d4a71a7f2965cdf73cef8
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
118 schema:name Clinical Sciences
119 rdf:type schema:DefinedTerm
120 sg:journal.1076985 schema:issn 0925-5710
121 1865-3774
122 schema:name International Journal of Hematology
123 rdf:type schema:Periodical
124 sg:pub.10.1007/s12185-017-2390-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099728472
125 https://doi.org/10.1007/s12185-017-2390-2
126 rdf:type schema:CreativeWork
127 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
128 https://doi.org/10.1038/bmt.2012.244
129 rdf:type schema:CreativeWork
130 sg:pub.10.1038/leu.2013.313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026245496
131 https://doi.org/10.1038/leu.2013.313
132 rdf:type schema:CreativeWork
133 sg:pub.10.1038/leu.2015.356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035584393
134 https://doi.org/10.1038/leu.2015.356
135 rdf:type schema:CreativeWork
136 sg:pub.10.1038/s41408-018-0071-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1103640953
137 https://doi.org/10.1038/s41408-018-0071-x
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1002/ajh.24883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091157900
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1002/cpt.550 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040390603
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/s0140-6736(15)01120-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009614699
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/s1470-2045(14)70442-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021088092
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1016/s1470-2045(16)30206-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042996950
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1056/nejmoa1606038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010220122
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1056/nejmoa1607751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026669052
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1080/19420862.2015.1007813 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058413271
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1182/blood-2015-10-646810 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017749361
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1182/blood-2016-03-705210 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040939015
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1182/blood-2017-05-785246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086132764
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1182/blood-2018-05-850727 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107092876
162 rdf:type schema:CreativeWork
163 https://doi.org/10.3324/haematol.2010.030759 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003844004
164 rdf:type schema:CreativeWork
165 https://doi.org/10.3324/haematol.2018.194118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107121220
166 rdf:type schema:CreativeWork
167 https://doi.org/10.3324/haematol.2018.194282 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107121218
168 rdf:type schema:CreativeWork
169 https://doi.org/10.4049/jimmunol.1003032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051064690
170 rdf:type schema:CreativeWork
171 https://www.grid.ac/institutes/grid.414927.d schema:alternateName Kameda Medical Center
172 schema:name Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan.
173 Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan. hiro.k2302@gmail.com.
174 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...